Form 4 for GNLX GENELUX Corp
Accepted 2024-12-20 00:00:00 ET · period of report 2024-12-18 · accession 0001415889-24-030004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-20 | 2024-12-18 | GNLX | Cappello Joseph | VP, Pharmaceutical Development | A - Grant | $0.00 | +29.0K | 43.7K | +198% | $0 |
| D | 2024-12-20 | 2024-12-18 | GNLX | Cappello Joseph | VP, Pharmaceutical Development | A - Grant | $0.00 | +39.0K | 39.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-18 | A | A | 29,000 | $0.00 | 43,653 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2024-12-18 | A | A | 39,000 | $0.00 | 39,000 | D | $2.29 · — to 2034-12-17 | 39,000 Common Stock | (F2) 25% of the shares vest on August 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter. |